Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known asCD66e (Cluster ofDifferentiation66e), is a member of thecarcinoembryonic antigen (CEA)gene family.[3]
In the literature, CEACAM5 is often used as a synonym for cancer embryonic antigen (CEA), a well-known biomarker of many types of malignancies, such as colorectal cancer and non-small-cell lung cancer.[4][5] Its primary function in the embryonic intestine and colon tumors is adhesion between epithelial cells.[6] Also, it plays a significant role in the inhibition of differentiation[7] and apoptosis[8] in colon cells. There are evidences that high CEACAM5 expression is firmly associated with theCD133-positive colorectalcancer stem cells.[9] High CEACAM5 expression has also been identified in ~25% of patients with advanced non-squamous (NSq) non-small cell lung cancer (NSCLC) detectable via IHC (immunohistochemistry).[10][11]
^Beauchemin N, Arabzadeh A (December 2013). "Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis".Cancer and Metastasis Reviews.32 (3–4):643–671.doi:10.1007/s10555-013-9444-6.PMID23903773.S2CID10344352.
^Benchimol S, Fuks A, Jothy S, Beauchemin N, Shirota K, Stanners CP (April 1989). "Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule".Cell.57 (2):327–334.doi:10.1016/0092-8674(89)90970-7.PMID2702691.S2CID30740594.
^Ordoñez C, Screaton RA, Ilantzis C, Stanners CP (July 2000). "Human carcinoembryonic antigen functions as a general inhibitor of anoikis".Cancer Research.60 (13):3419–3424.PMID10910050.
^Gisina A, Novikova S, Kim Y, Sidorov D, Bykasov S, Volchenko N, et al. (2021-01-01). "CEACAM5 overexpression is a reliable characteristic of CD133-positive colorectal cancer stem cells".Cancer Biomarkers.32 (1):85–98.doi:10.3233/CBM-203187.PMID34092615.S2CID235359543.
^LaPointe N, Hertle N, Hsu SC, Kellis J, King N, Littrell J, et al. (2021-05-20). "Validation of an immunohistochemical assay, CEACAM5 IHC 769, under development for use with the antibody-drug conjugate tusamitamab ravtansine (SAR408701)".Journal of Clinical Oncology.39 (15_suppl) e21030.doi:10.1200/JCO.2021.39.15_suppl.e21030.ISSN0732-183X.S2CID236398737.
Willcocks TC, Craig IW (November 1990). "Characterization of the genomic organization of human carcinoembryonic antigen (CEA): comparison with other family members and sequence analysis of 5' controlling region".Genomics.8 (3):492–500.doi:10.1016/0888-7543(90)90036-T.PMID2286372.
Barnett T, Zimmermann W (1990). "Workshop report: proposed nomenclature for the carcinoembryonic antigen (CEA) gene family".Tumour Biology.11 (1–2):59–63.doi:10.1159/000217643.PMID2309067.
Barnett T, Goebel SJ, Nothdurft MA, Elting JJ (July 1988). "Carcinoembryonic antigen family: characterization of cDNAs coding for NCA and CEA and suggestion of nonrandom sequence variation in their conserved loop-domains".Genomics.3 (1):59–66.doi:10.1016/0888-7543(88)90160-7.PMID3220478.
Zimmermann W, Weber B, Ortlieb B, Rudert F, Schempp W, Fiebig HH, et al. (May 1988). "Chromosomal localization of the carcinoembryonic antigen gene family and differential expression in various tumors".Cancer Research.48 (9):2550–2554.PMID3356015.
Oikawa S, Nakazato H, Kosaki G (January 1987). "Primary structure of human carcinoembryonic antigen (CEA) deduced from cDNA sequence".Biochemical and Biophysical Research Communications.142 (2):511–518.Bibcode:1987BBRC..142..511O.doi:10.1016/0006-291X(87)90304-4.PMID3814146.
Maruyama K, Sugano S (January 1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides".Gene.138 (1–2):171–174.doi:10.1016/0378-1119(94)90802-8.PMID8125298.
Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, Suyama A, Sugano S (October 1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library".Gene.200 (1–2):149–156.doi:10.1016/S0378-1119(97)00411-3.PMID9373149.
Wirth T, Soeth E, Czubayko F, Juhl H (2002). "Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth".Clinical & Experimental Metastasis.19 (2):155–160.doi:10.1023/A:1014566127493.PMID11964079.S2CID3138022.
PDBe-KB provides an overview of all the structure information available in the PDB for Human Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)
